Cancer Research Consortium of West Michigan

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex TEMPORARY CLOSURE

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations dated 11/26/2019

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.

Molecular Analysis for Therapy Choice (MATCH)

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol J: EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol L: EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1C: EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1F: EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1K: EAY131-Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)

Work Ability in Young Adult Survivors (WAYS)

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 Years of Age at Enrollment.
2. Standard Risk 1
   Patient must be < 11 Years of Age at Enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 Years of Age at Enrollment.

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification